Systematic review of 64 studies in advanced breast cancer: elevated baseline ctDNA was associated with shorter PFS (n=2,586; pooled HR 2.0) and OS (n=2,454; HR 2.6); unfavourable on-treatment ctDNA changes were linked to worse PFS (HR 2.5) and OS (HR 2.4).
Meta-analysisn = 64 studies
Ottosen et al. Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis